Inside informationEnglish
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Nanobiotix
- Filed
- 20/04/2026, 08:30
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 112538_20260420